home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605d.zip
/
M9651067.TXT
< prev
next >
Wrap
Text File
|
1996-03-30
|
3KB
|
50 lines
Document 1067
DOCN M9651067
TI Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with
chimeric-multirestricted lipopeptides.
DT 9505
AU Sauzet JP; Deprez B; Martinon F; Guillet JG; Gras-Masse H; Gomard E;
Laboratoire d'Immunologie des Interactions Cellulaires et; Moleculaires,
INSERM U152, Institut Cochin de Genetique; Moleculaire, Paris, France.
SO Vaccine. 1995 Oct;13(14):1339-45. Unique Identifier : AIDSLINE
MED/96155144
AB Cytotoxic T lymphocytes (CTL) play a major role in protective immunity
against viral diseases. However, the antigenic formulations that can be
used in vaccinations able to generate virus-specific CTL responses in
vivo have yet to be defined. We have previously shown that
HIV-1-specific CTL can be elicited in mice by injecting without adjuvant
a synthetic peptide of the envelope glycoprotein that has been modified
by the addition of a simple lipid tail to the end of the sequence
(lipopeptide). The present study set out to address the question of
whether such immunogens may be appropriate for preparing a human
synthetic vaccine. We first showed that CTL were effectively induced by
lipopeptides when given s.c. or i.p. We evidenced that the in vivo
induction required stimulation of a concomitant specific T helper cell
response, implying the presence of at least one CD4 epitope in the
synthetic sequence used. Bearing in mind the particular properties that
would be required in a prospective human peptide vaccine, we conceived a
strategy in which a virus-specific CTL response could be generated in
mice of different haplotypes using a single lipopeptide. We therefore
tested a lipopeptide construct that integrated a synthetic sequence
having three colinear epitopes of the influenza virus nucleoprotein,
each restricted to a different H-2 haplotype. We found that a CTL
response could be elicited to all three epitopes of this chimeric
multirestricted lipopeptide construct. Finally, we have attempted to
estimate the duration of the responses; strong CTL activities were still
present up to six months after the last injection. These findings
indicate that this approach may be suitable for developing a synthetic
vaccine for human use.
DE Animal Chick Embryo Chimeric Proteins/*IMMUNOLOGY/*PHARMACOLOGY
CD8-Positive T-Lymphocytes/IMMUNOLOGY Epitopes/IMMUNOLOGY Haplotypes
Influenza Vaccine/PHARMACOLOGY Lipoproteins/*IMMUNOLOGY/*PHARMACOLOGY
Mice Mice, Inbred Strains Nucleoproteins/IMMUNOLOGY Orthomyxovirus
Type A, Human/IMMUNOLOGY Orthomyxoviruses Type B/*IMMUNOLOGY
Sensitivity and Specificity T-Lymphocytes, Cytotoxic/DRUG
EFFECTS/*IMMUNOLOGY T-Lymphocytes, Helper-Inducer/DRUG
EFFECTS/IMMUNOLOGY Time Factors Viral Proteins/IMMUNOLOGY JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).